Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

Combinations of cisplatin–irinotecan and cisplatin–etoposide are active and well tolerated in patients with both small-cell lung cancer (SCLC) and nonsmall-cell lung cancer (NSCLC). To define the recommended dose for phase II trials of irinotecan combined with cisplatin and etoposide in chemonaive p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Hojo, F, Matsumoto, T, Ohmatsu, H, Goto, K, Kodama, T, Eguchi, K, Shinkai, T, Tamura, T, Ohe, Y, Kunitoh, H, Yoshimura, K, Saijo, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377075/
https://www.ncbi.nlm.nih.gov/pubmed/12644814
http://dx.doi.org/10.1038/sj.bjc.6600800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377075/
https://www.ncbi.nlm.nih.gov/pubmed/12644814
http://dx.doi.org/10.1038/sj.bjc.6600800

Ejemplares similares